Skip to main content

Table 1 Baseline demographic and angiographic characteristics

From: Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up

VariablePitavastatin 1 mg (n = 337)Pitavastatin 4 mg (n = 330)p-value
Age (years)64.1 ± 11.962.2 ± 11.80.04
Male sex230 (68.2)253 (76.7)0.02
Body mass index (kg/m2)24.3 ± 3.024.8 ± 3.10.03
Diagnosis0.99
 Unstable angina210 (72.7)209 (72.3) 
 Non-ST elevation MI45 (15.6)45 (15.6) 
 ST elevation MI34 (11.8)35 (12.1) 
Risk factors
 Hypertension194 (57.6%)183 (55.5%)0.59
 Smoking status0.01
  Current smoker66 (19.6%)98 (29.7%) 
  Ex-smoker64 (19.0%)61 (18.5%) 
  Never smoker207 (61.4%)171 (51.8%) 
 Alcoholics54 (16.0%)63 (19.1%)0.31
 Prior MI19 (5.4%)13 (3.8%)0.29
Medication on admission
 Aspirin335 (99.4%)330 (100%)0.50
 Clopidogrel295 (87.5%)263 (79.7%)0.01
 Ticagrelor49 (14.5%)63 (19.1%)0.12
 Prasugrel10 (3.0%)29 (8.8%)0.001
 ACE inhibitor69 (20.5%)60 (18.2%)0.49
 ARB114 (33.8%)94 (28.5%)0.16
 β-blocker142 (42.1%)158 (47.9%)0.14
 CCB110 (32.6%)116 (35.2%)0.51
 Diuretics61 (18.1%)54 (16.4%)0.61
Laboratory findings
 Total cholesterol (mg/dL)174.2 ± 41.7185.2 ± 49.7< 0.01
 Triglyceride (mg/dL)144.0 ± 105.9164.5 ± 175.00.08
 HDL cholesterol (mg/dL)43.8 ± 11.242.9 ± 9.90.28
 LDL cholesterol (mg/dL)119.6 ± 34.5127.5 ± 37.10.01
 Creatinine (mg/dL)1.1 ± 1.50.9 ± 0.20.06
 Uric acid (mg/dL)5.5 ± 1.55.8 ± 1.60.09
 hsCRP (mg/L)5.9 ± 12.67.4 ± 17.50.26
 Fasting glucose (mmol/L)113.6 ± 27.8116.4 ± 28.40.28
 HbA1c (%)5.8 ± 0.45.8 ± 0.30.89
  1. Values are presented as mean ± standard deviation or n (%)
  2. ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, CCB calcium channel blocker, HbA1c hemoglobin A1c, HDL high-density lipoprotein, hsCRP high-sensitivity C-reactive protein, LDL low-density lipoprotein, MI myocardial infarction